ENVB · Enveric Biosciences, Inc. · Financials
$1.48
+0.06 (+4.23%)
At close · Sep 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.36M
Shares
4.48M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$39.91M
-7.2%
FY2019
Net Income
-$8.77M
+8.4%
FY2025
Gross Margin
20.42%
-0.5pp
FY2019
Operating Margin
-5.75%
+10.9pp
FY2019
Diluted EPS
-$36.24
+84.1%
FY2025
Operating Cash Flow
-$8.14M
-5.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $35.41M | — | — | — | — | — | — | $39.91M | $43M | $48.59M | $36.15M | $20.26M | — | — | — | — | — | |
| -$571 | -$106 | $219 | $3708 | -$5249 | — | — | — | — | — | — | $89.92K | — | — | — | — | — | |
| $28.09M | — | — | — | — | — | — | $31.76M | $34.01M | $38.36M | $29.22M | $13.39M | — | — | — | — | — | |
| $7.32M | — | — | — | — | — | — | $8.15M | $8.98M | $10.24M | $6.93M | $6.87M | — | — | — | — | — | |
| — | — | — | — | — | — | — | 20.42% | 20.89% | 21.07% | 19.17% | 33.91% | — | — | — | — | — | |
| $2.48M | $2.78M | $2.84M | $7.25M | $8.03M | $4.79M | $174.08K | — | — | — | $55.1K | — | — | — | — | — | — | |
| $1.28M | — | — | — | — | — | — | — | — | — | $417.25K | $119.85K | — | — | — | — | — | |
| $6.1M | $5.79M | $6.45M | $8.85M | $11.61M | $20.5M | — | — | — | — | $8.55M | $5.72M | -$32.81K | -$27.21K | $22.69K | $31.4K | $35.88K | |
| $16.8M | — | — | — | — | $20.5M | $5.32M | $2.3M | $10.79M | $18.51M | $9.36M | — | — | — | — | — | — | |
| — | $42.18K | $168.75K | $168.75K | $168.75K | $643.33K | $120.87K | $2.3M | $2.9M | $3.2M | $1.4M | $164.75K | — | — | — | — | — | |
| $153.92K | $200.86K | $337.49K | $343.98K | $327.91K | $656.64K | $120.87K | $2.27M | $2.9M | $3.22M | $1.36M | $166.21K | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $400K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $14.48M | $16.13M | $21.13M | $12.31M | $7.66M | — | — | — | — | — | |
| -$8.73M | -$8.77M | -$9.63M | -$16.45M | -$27.42M | -$64.62M | -$5.62M | -$2.3M | -$7.15M | -$10.9M | -$5.38M | -$793.98K | $32.81K | $27.21K | -$22.69K | -$31.4K | -$35.88K | |
| — | — | — | — | — | — | — | -5.75% | -16.62% | -22.42% | -14.88% | -3.92% | — | — | — | — | — | |
| -$8.57M | -$8.57M | -$9.29M | -$16.1M | -$27.09M | -$63.97M | -$5.5M | -$31.24K | -$4.24M | -$7.68M | -$4.02M | -$627.77K | — | — | — | — | — | |
| $1122 | — | — | — | $5249 | $10.32K | $445.25K | $81.82K | $729.9K | $575.04K | $751.07K | $238.47K | — | — | — | — | — | |
| -$569 | $2461 | $66.21K | -$814.38K | $7.46M | $8.19M | -$1.25M | $114.14K | -$3.4M | -$570.04K | -$1.15M | -$148.55K | — | — | — | — | — | |
| — | $1707 | $21.62K | $208.75K | $3.47M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$8.73M | -$8.77M | -$9.57M | -$17.26M | -$19.96M | -$56.43M | -$6.86M | -$5.22M | -$10.55M | -$11.47M | -$6.53M | — | -$32.81K | $1289 | -$22.69K | -$31.4K | -$35.88K | |
| — | — | $8930 | $28.91K | -$1.49M | -$7.45M | — | $388.66K | $6.35M | -$2.39M | -$3.75M | -$128.46K | $833 | $1450 | $1931 | $1985 | $3566 | |
| -$8.73M | -$8.77M | -$9.57M | -$17.29M | -$18.47M | -$48.98M | -$6.86M | -$2.41M | -$16.9M | -$9.07M | -$2.78M | -$814.08K | -$33.64K | -$161 | -$24.62K | -$33.38K | -$39.44K | |
| — | — | — | — | — | — | — | -6.04% | -39.3% | -18.67% | -7.69% | -4.02% | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $0 | $3382 | — | — | — | — | — | — | |
| — | -$12.13M | -$9.57M | -$17.46M | -$18.8M | -$48.98M | — | -$6.03M | -$19.48M | -$11.16M | -$2.78M | — | — | — | — | — | — | |
| -$8.75M | -$8.76M | -$9.6M | -$17.49M | -$19.31M | -$48.83M | -$7.03M | -$6.06M | -$19.43M | -$11.12M | -$2.79M | -$814.08K | — | — | — | — | — | |
| USD/shares | -$11.85 | -$36.24 | -$228.48 | -$1,455.48 | -$35,100.00 | -$279,963.00 | — | -$1,528,200.00 | -$11,053,800.00 | -$405,000.00 | -$113,400.00 | -$37,800.00 | — | — | — | — | — |
| USD/shares | -$11.85 | -$36.24 | -$228.48 | -$1,455.48 | -$35,100.00 | — | — | -$1,528,200.00 | -$11,053,800.00 | -$405,000.00 | -$113,400.00 | -$37,800.00 | — | — | — | — | — |
| shares | — | 334.72K | 41.91K | 11.99K | 535.5581 | 174.9419 | 42.6192 | 39.164 | 1.7622 | 27.7459 | 24.2011 | 20.5578 | 28.2267 | 22.4852 | 22.4852 | 15.673 | 12.037 |
| shares | — | 334.72K | 41.91K | 11.99K | 535.5581 | 174.9415 | 42.6192 | 3.9422 | 1.7622 | 27.7459 | 24.2011 | 20.5578 | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.06×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.24×
Peer medians compare against the 174 similar-size Biotechnology companies (of 536 listed).